Open Access
Subscription Access
Exploring Pharmacological Interventions for Alcoholic Fatty Liver Disease
Abstract
Alcoholic Fatty Liver Disease (AFLD) is a common and reversible condition manifested by accumulation of fat in the liver due to excessive alcohol consumption. N_ acetyl cysteine (NAC) behaves as a precursor to glutathione, a powerful antioxidant. NAC assists counteract oxidative stress in the liver, decreasing inflammation and stopping further liver damage. Pentoxyfylline shows anti-inflammatory properties by inhibiting tumor necrosis factor_ alpha (TNF_ alpha) a cytokine participated in liver inflammation. Pentoxyfylline has exhibited an improvement in decreasing liver inflammation and improving liver function. A thiazolidinedione, pioglitazone enhances insulin sensitivity and decreases inflammation. This drug treats AFLD by addressing insulin resistance and enhancing fat metabolic in the liver. Ursodeoxycholic Acid (UDCA) is used for treating cholestatic liver diseases. UDCA has shown heoato protective effects I. AFL. Fish oil (Onega_ 3 polyunsaturated fatty acids) has shown it's potential in AFLD. Fish oil reduces liver inflammation and enhance lipid metabolism. Tocopherol (Vitamin E) supplementation has exhibited potential in enhance liver histology in patients with AFLD. Orlistat may show beneficial effects in AFLD. It performs by stopping the absorption of dietary fat, potentially decreasing fat accumulation in the liver. Finally it is concluded clouded that pharmacological interventions for alcoholic fatty liver disease focus on mitigating inflammation, decreasing oxidative stress and improving metabolic processes within the liver.
References
Hussen, N., Zhu, L., Tetangco, E., & Ellison, S. (2018). Hepatoptosis in a Patient with Alcoholic Hepatitis. Official journal of the American College of Gastroenterology| ACG, 113(11), 1581.
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2018). Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Research, 7.
Torruellas, C., French, S. W., & Medici, V. (2014). Diagnosis of alcoholic liver disease. World journal of gastroenterology: WJG, 20(33), 11684.
Edula, R. G., Muthukuru, S., Moroianu, S., Wang, Y., Lingiah, V., Fung, P., & Pyrsopoulos, N. T. (2018). CA-125 significance in cirrhosis and correlation with disease severity and portal hypertension: a retrospective study. Journal of clinical and translational hepatology, 6(3), 241.
Mathurin, P., & Bataller, R. (2015). Trends in the management and burden of alcoholic liver disease. Journal of hepatology, 62(1), S38-S46.
Thursz, M., Forrest, E., Roderick, P., Day, C., Austin, A., O'Grady, J., ... & Ternent, L. (2015). The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2× 2 factorial randomised controlled trial. Health Technology Assessment (Winchester, England), 19(102), 1-104.
Haflidadottir, S., Jonasson, J. G., Norland, H., Einarsdottir, S. O., Kleiner, D. E., Lund, S. H., & Björnsson, E. S. (2014). Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC gastroenterology, 14, 1-10.
Martin, A. P., Bartels, M., Hauss, J., & Fangmann, J. (2007, December). Overview of the MELD score and the UNOS adult liver allocation system. In Transplantation proceedings (Vol. 39, No. 10, pp. 3169-3174). Elsevier.
Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P., ... & United Network for Organ Sharing Liver Disease Severity Score Committee. (2003). Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology, 124(1), 91-96.
Ellison, L. M., Pinto, P. A., Kim, F., Ong, A. M., Patriciu, A., Stoianovici, D., ... & Kavoussi, L. R. (2004). Telerounding and patient satisfaction after surgery. Journal of the American College of Surgeons, 199(4), 523-530.
Refbacks
- There are currently no refbacks.